These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases. Valverde AM; Reed SD; Schulman KA Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684 [TBL] [Abstract][Full Text] [Related]
26. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
27. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. Pariser AR; Xu K; Milto J; Coté TR Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390 [TBL] [Abstract][Full Text] [Related]
28. A new era of hope for the world's most neglected diseases. The PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790 [TBL] [Abstract][Full Text] [Related]
29. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Kumar Kakkar A; Dahiya N Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189 [TBL] [Abstract][Full Text] [Related]
30. Duel over discounts. Pharma, providers at odds over 'orphan drugs'. Daly R Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763 [No Abstract] [Full Text] [Related]
31. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
32. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related]
33. Translation of rare disease research into orphan drug development: disease matters. Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412 [TBL] [Abstract][Full Text] [Related]
34. Rare or orphan diseases -- a useful political concept. Baxter P Dev Med Child Neurol; 2012 Jul; 54(7):579. PubMed ID: 22607366 [No Abstract] [Full Text] [Related]
35. The balancing act of orphan drug pricing. The Lancet Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396 [No Abstract] [Full Text] [Related]
36. The orphan drug backlash. Maeder T Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333 [No Abstract] [Full Text] [Related]